Literature DB >> 23575888

Comparison of radiation exposure and cost between dynamic computed tomography and sestamibi scintigraphy for preoperative localization of parathyroid lesions.

Catherine A Madorin1, Randall Owen, Brian Coakley, Hannah Lowe, Kee-Hyun Nam, Kaare Weber, Leon Kushnir, Jose Rios, Eric Genden, Puneet S Pawha, William B Inabnet.   

Abstract

IMPORTANCE: Dynamic computed tomography (CT) is emerging as a first-line alternative to sestamibi scintigraphy for preoperative localization of parathyroid lesions. In recent years, there has been increased concern over the impact of radiation exposure from medical imaging, as well as on the cost of diagnostic medical procedures. An ideal diagnostic procedure would be cost effective while minimizing hazardous exposures and complication rates.
OBJECTIVE: To compare the radiation dose and financial cost of dynamic CT with sestamibi scintigraphy. DESIGN, SETTING, AND PATIENTS: A retrospective review of 263 patients at a large, urban, tertiary referral center who underwent either dynamic parathyroid CT or sestamibi scintigraphy for any etiology of hyperparathyroidism from 2006 through 2010. MAIN OUTCOMES AND MEASURES: The 2 primary study outcomes were radiation exposure measured in millisieverts (mSv) and medical charges for the respective diagnostic procedures. The study was conducted with the hypothesis that dynamic parathyroid CT would have slightly greater radiation exposure with similar cost to sestamibi scintigraphy.
RESULTS: Dynamic parathyroid CT and sestamibi scintigraphy delivered mean radiation doses of 5.56 and 3.33 mSv, respectively (P < .05). Charges totaled $1296 for thin-cut dynamic parathyroid CT and a mean of $1112 for sestamibi scintigraphy, depending on the type and amount of radiotracer injected. Although multiphase CT scanning took less than 5 minutes, sestamibi scintigraphy lasted a mean time of 306 minutes. A total of 62 of 119 patients (52%) in the CT group have undergone operative treatment to date, whereas all patients in the sestamibi arm underwent operative treatment of their hyperparathyroidism. Of the patients who underwent a surgical procedure, CT correctly identified the side of the parathyroid adenoma in 54 of 62 patients (87%), while sestamibi scintigraphy only correctly lateralized 90 of 122 adenomas (74%) as confirmed by exploratory surgery, intraoperative parathyroid hormone levels, and pathologic features. A dynamic parathyroid CT correctly predicted multiglandular disease in 1 of 7 patients (14%), while sestamibi scintigraphy correctly predicted multiglandular disease in 8 of 23 patients (35%). CONCLUSIONS AND RELEVANCE: In patients who underwent directed parathyroid surgery, dynamic CT is comparable to sestamibi scintigraphy in patients with hyperparathyroidism. Although CT delivers a higher dose of radiation, the average background radiation exposure in the United States is 3 mSv/y, and added exposures of less than 15 mSv are considered low risk for carcinogenesis. Overall, dynamic parathyroid CT is a safe, cost-effective alternative to sestamibi scintigraphy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23575888     DOI: 10.1001/jamasurg.2013.57

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  17 in total

1.  4D-Dynamic Contrast-Enhanced MRI for Preoperative Localization in Patients with Primary Hyperparathyroidism.

Authors:  J L Becker; V Patel; K J Johnson; M Guerrero; R R Klein; G F Ranvier; R P Owen; P Pawha; K Nael
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

2.  Minimally invasive parathyroid surgery.

Authors:  Randall P Owen; Carl E Silver; Ashok R Shaha; Phillip K Pellitteri; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-01-31       Impact factor: 2.503

Review 3.  [Localization of parathyroid adenomas with C11-methionine PET-CT].

Authors:  T Weber; M Luster
Journal:  Chirurg       Date:  2014-07       Impact factor: 0.955

4.  Dynamic CT for parathyroid disease: are multiple phases necessary?

Authors:  P Raghavan; C R Durst; D A Ornan; S Mukherjee; M Wintermark; J T Patrie; W Xin; A L Shada; J B Hanks; P W Smith
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-05       Impact factor: 3.825

5.  Clinical efficacy of 2-phase versus 4-phase computed tomography for localization in primary hyperparathyroidism.

Authors:  Adriana G Ramirez; Amber L Shada; Allison N Martin; Prashant Raghavan; Christopher R Durst; Sugoto Mukherjee; John R Gaughen; David A Ornan; John B Hanks; Philip W Smith
Journal:  Surgery       Date:  2016-06-11       Impact factor: 3.982

6.  Detection of parathyroid adenomas using a monophasic dual-energy computed tomography acquisition: diagnostic performance and potential radiation dose reduction.

Authors:  Carlos Leiva-Salinas; Lucia Flors; Christopher R Durst; Qinghua Hou; James T Patrie; Max Wintermark; Sugoto Mukherjee
Journal:  Neuroradiology       Date:  2016-09-02       Impact factor: 2.804

7.  Dynamic 4D MRI for Characterization of Parathyroid Adenomas: Multiparametric Analysis.

Authors:  K Nael; J Hur; A Bauer; R Khan; A Sepahdari; R Inampudi; M Guerrero
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-10       Impact factor: 3.825

8.  Evaluation of the radiation dose exposure and associated cancer risks in patients having preoperative parathyroid localization.

Authors:  S R Moosvi; S Smith; J Hathorn; T Groot-Wassink
Journal:  Ann R Coll Surg Engl       Date:  2017-05       Impact factor: 1.891

9.  The use of computed tomography as a first-line imaging modality in patients with primary hyperparathyroidism.

Authors:  Mechteld C de Jong; K Jamal; S Morley; T Beale; T Chung; S Jawad; S Hurel; H Simpson; U Srirangalingam; S E Baldeweg; V Rozalén García; S Otero; M Shawky; T E Abdel-Aziz; T R Kurzawinski
Journal:  Hormones (Athens)       Date:  2020-05-13       Impact factor: 2.885

10.  Preoperative localization of hyperfunctioning parathyroid glands with 4D-CT.

Authors:  Anke Katrin Lundstroem; Waldemar Trolle; Christian Hjort Soerensen; Peter Sand Myschetzky
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-03-14       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.